Triple administration of osimertinib followed by chemotherapy for advanced lung adenocarcinoma: A case report
Open Access
- 16 April 2021
- journal article
- research article
- Published by Baishideng Publishing Group Inc. in World Journal of Clinical Cases
- Vol. 9 (11), 2627-2633
- https://doi.org/10.12998/wjcc.v9.i11.2627
Abstract
Osimertinib is the recommended first-line treatment for adult patients with epidermal growth factor receptor (EGFR) mutation positive advanced or metastatic non-small cell lung cancer (NSCLC). However, primary or acquired resistance to EGFR-tyrosine kinase inhibitors (EGFR-TKIs) seems inevitable, and when drug-resistance occurs during treatment with osimertinib, the standard of care is to discontinue the TKI. A 57-year-old female patient with lung adenocarcinoma presented with an irritating cough accompanied by chest distress of one month duration. An enhanced head magnetic resonance imaging scan showed brain metastases. An EGFR mutation (exon 21 L858R) was detected in pleural fluid. The patient was treated with oral osimertinib (80 mg once daily) from January 2018 but developed progressive disease on December 2018. She was then successfully treated with re-challenge and tri-challenge with osimertinib (80 mg once daily) by resensitization chemotherapy twice after the occurrence of drug-resistance to osimertinib, and to date has survived for 31 mo. This case may provide some selective therapeutic options for NSCLC patients with acquired drug-resistance who were previously controlled on osimertinib treatment.Keywords
This publication has 13 references indexed in Scilit:
- Efficacy and Safety of Gefitinib as Third-line Treatment in NSCLC Patients With Activating EGFR Mutations Treated With First-line Gefitinib Followed by Second-line ChemotherapyAmerican Journal of Clinical Oncology, 2019
- Newer-Generation EGFR Inhibitors in Lung Cancer: How Are They Best Used?Cancers, 2019
- Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI?Nature Reviews Clinical Oncology, 2018
- Liquid biopsies come of age: towards implementation of circulating tumour DNANature Reviews Cancer, 2017
- Predictive factors for EGFR -tyrosine kinase inhibitor retreatment in patients with EGFR -mutated non-small-cell lung cancer – A multicenter retrospective SEQUENCE studyLung Cancer, 2017
- Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases ActivityClinical Cancer Research, 2016
- Effect of EGFR-TKI retreatment following chemotherapy for advanced non-small cell lung cancer patients who underwent EGFR-TKI2014
- Retreatment of gefitinib in patients with non-small-cell lung cancer who previously controlled to gefitinib: A single-arm, open-label, phase II studyLung Cancer, 2012
- Effect of gefitinib re-challenge to initial gefitinib responder with non-small cell lung cancer followed by chemotherapyLung Cancer, 2010
- Erlotinib after Failure of Gefitinib in Patients with Advanced Non-small Cell Lung Cancer Previously Responding to GefitinibJournal of Thoracic Oncology, 2008